<DOC>
	<DOCNO>NCT00519727</DOCNO>
	<brief_summary>The primary purpose trial ass safety ISIS 325568 give increase single dos assess safety dos give multiple time .</brief_summary>
	<brief_title>Safety Study ISIS 325568 Healthy Volunteers</brief_title>
	<detailed_description>To evaluate safety single subcutaneous injection ISIS 325568 administer four increase dose level ( 50 , 100 , 200 , 400 mg/week ) evaluate safety tolerability multiple dos ISIS 325568 ( three intravenous dos Study Week 1 , follow weekly subcutaneous administration 5 week ) four dose level</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Age 18 65 year 2 . Males female . Females must nonpregnant nonlactating , either surgically sterile ( hysterectomy , oophorectomy , tubal ligation ) postmenopausal . Males must surgically sterile , abstinent engage sexual relation childbearing potential , subject partner must use acceptable contraceptive method trial 9 week last dose study drug . 3 . Give write informed consent participate study availability study requirement 4 . Fasting plasma glucose ≤ upper limit laboratory 's reference range ( ULN ) 5 . HbA1C ≤ ULN 6 . BMI &lt; 30 kg/m2 1 . Clinically significant abnormality medical history physical examination 2 . Abnormalities laboratory examination ( ALT &gt; ULN , AST &gt; ULN , bilirubin &gt; ULN , creatinine &gt; ULN , urine protein positive urine dipstick , platelet &lt; low limit normal clinically significant laboratory finding ) 3 . History clinically significant abnormality coagulation parameter 4 . Positive test result HIV , hepatitis B virus , and/or hepatitis C virus 5 . Active infection require antiviral antimicrobial therapy 6 . Subjects chronic acute prescription medication may permit discussion Isis Medical Monitor . 7 . Malignancy ( exception basal squamous cell carcinoma skin adequately treat recurrence &gt; 1 year ) 8 . Any concurrent condition , opinion Investigator , would preclude participation study interfere compliance 9 . History alcohol drug abuse 10 . Undergoing undergone treatment another investigational drug , biologic agent device within 90 day prior Screening . 11 . Blood donation within three month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>diabetes</keyword>
</DOC>